Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:50:18 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:INCY - INCYTE CORPORATION - http://www.incyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q9.751.08·52.005.051.68+0.501.01,564.379,61118,39650.90  51.85  50.8775.74  50.2717:35:10Apr 2315 min RT 2¢

Recent Trades - Last 10 of 18396
Time ETExPriceChangeVolume
17:35:10Q51.9840.80425
16:20:01Q51.680.501,330
16:06:39Q51.680.5044
16:02:32Q51.680.5025
16:02:32Q51.680.509
16:02:31Q51.680.50296
16:02:31Q51.680.504,243
16:02:31Q51.680.501,434
16:02:30Q51.680.5099
16:02:30Q51.680.5033

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-23 07:00U:INCYNews ReleaseIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
2024-04-11 08:00U:INCYNews ReleaseIncyte to Report First Quarter Financial Results
2024-04-01 08:30U:INCYNews ReleaseIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
2024-03-29 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-10 16:05U:INCYNews ReleaseIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura(TM)) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
2024-03-10 16:05U:INCYNews ReleaseIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
2024-03-04 08:00U:INCYNews ReleaseNew Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
2024-02-29 10:19U:INCYNews ReleaseIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
2024-02-29 07:30U:INCYNews ReleaseKnight Therapeutics Announces Launch of Minjuvi(TM) in Brazil
2024-02-27 16:08U:INCYNews ReleaseIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
2024-02-15 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2024-02-13 07:00U:INCYNews ReleaseIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
2024-02-05 16:46U:INCYNews ReleaseIncyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi ‚ ®)
2024-01-23 08:00U:INCYNews ReleaseIncyte to Report Fourth Quarter and Year-End 2023 Financial Results
2024-01-08 08:30U:INCYNews ReleaseIncyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2023-11-02 09:00U:INCYNews ReleaseIncyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
2023-10-31 07:00U:INCYNews ReleaseIncyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
2023-10-18 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2023-10-16 08:00U:INCYNews ReleaseIncyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023